A three-year-old biotech just filed to go public with plans to take on Dupixent, immunology's $18 billion juggernaut. Attovia Therapeutics has $255 million in venture backing, miniaturized antibodies, and a very long road ahead.
Dupixent made nearly $18 billion last year. It treats eczema, asthma, and a growing list of inflammatory diseases. More than 1 million patients are being treated with it globally. And a company that's barely three years old, still running its first clinical trial, just told Wall Street it wants a piece of that pie.
Attovia Therapeutics filed for an IPO this week, planning to list on the Nasdaq under the ticker ATTO. The underwriter lineup reads like a who's who of biotech banking: Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets. For a Phase 1 company, that's a strong roster. It signals that serious money thinks there's something worth buying here.
But going after Dupixent with early-stage drugs? That's like challenging the reigning heavyweight champion while you're still lacing up your gloves.
A Platform Built on Tiny Antibodies
Attovia didn't start from scratch. It spun out of Alamar Biosciences in 2023, taking with it an exclusive license to something called the Attobody platform. Think of Attobodies as miniaturized antibodies: two small protein fragments linked together, each grabbing a different spot on the same target. The result is a molecule that latches on with unusually strong grip.
Why does that matter? Traditional antibodies like Dupixent block a receptor (a docking station on cells). Attovia's approach is different. Instead of blocking the docking station, it intercepts the signal before it arrives, trapping the inflammatory molecules (called cytokines) while they're still floating around in your bloodstream. The company believes this "ligand trap" strategy could work faster and last longer.
The lead drug, ATTO-1310, targets a cytokine called IL-31, which is one of the main drivers of itching in conditions like eczema. It's currently in a Phase 1 trial for chronic pruritus (persistent, unexplained itching) and could be dosed as infrequently as once every three months. Compare that to Dupixent's biweekly injections, and you can see the convenience angle.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Behind it sits ATTO-3712, a more ambitious molecule. This one is a bispecific, meaning it traps two cytokines at once: IL-13 (a key driver of skin inflammation) and IL-31 (the itch signal). Attovia is positioning this as the drug that could go head-to-head with Dupixent in atopic dermatitis, tackling both inflammation and itching in a single shot. It's currently in IND-enabling studies, the last step before human trials begin.
The Money Trail
Attovia isn't short on cash. Before this IPO filing, the company raised roughly $255 million across three venture rounds in rapid succession.
The $60 million Series A in June 2023 launched the company, led by Frazier Life Sciences with venBio and Illumina Ventures. A $105 million Series B followed, led by Goldman Sachs Asset Management. Then in April 2025, Deep Track Capital led a $90 million Series C that brought in a notable new name: Sanofi Ventures, the corporate venture arm of the company that co-owns Dupixent.
Read that again. Sanofi's own venture fund invested in a company explicitly designed to compete with Sanofi's biggest product. That's either sophisticated hedging or a sign that even Dupixent's parent sees room for improvement.
David, Meet Goliath
The scale mismatch here is staggering. Dupixent generated €15.7 billion (roughly $18.3 billion) in 2025 sales for Sanofi, growing over 25% year-over-year. In Q4 alone, it pulled in nearly $5 billion. It's approved in eight indications globally and holds the number-one position in prescriptions across its key markets. Sanofi expects high-single-digit revenue growth for 2026, with Dupixent as the engine.
Attovia, meanwhile, has zero approved products, zero revenue, and a lead drug that hasn't finished its first safety trial.
But investors aren't betting on today. They're betting on whether Attovia's science can carve out a niche in a market that keeps expanding. Dupixent blocks IL-4 and IL-13 signaling through a receptor called IL-4Rα; it doesn't directly touch IL-31. Patients who respond well to Dupixent but still suffer from intense itching represent a real gap. If ATTO-1310 or ATTO-3712 can fill that gap, the commercial opportunity doesn't require dethroning Dupixent entirely. Even a sliver of an $18 billion market is enormous.
Attovia Isn't Alone in the Ring
The race to build "Dupixent 2.0" is getting crowded. NM26-2198 is a bispecific targeting IL-4Rα and IL-31, already in Phase 1 for atopic dermatitis. Zai Lab's ZL-1503 dosed its first patient in a Phase 1/1b trial in December 2025, combining IL-13 and IL-31 receptor blockade. Generate Biomedicines has GB-7624, a pure IL-13 inhibitor, in Phase 1 with data expected in 2026. And Kymera Therapeutics is taking an oral approach with KT-621, a pill that degrades STAT6, a protein downstream of IL-4 and IL-13 signaling.
Each is making a slightly different bet on which cytokines matter most, and how to block them. Attovia's differentiator is its platform: biparatopic nanobodies with built-in half-life extension, potentially enabling quarterly dosing in a market where biweekly or monthly shots are the norm.
The IPO Window Is Open (for Now)
Attovia's timing isn't accidental. The biotech IPO market in 2026 has thawed considerably after years of deep freeze. Q1 2026 saw biopharma companies raise $1.7 billion through IPOs, the strongest quarter since 2021. The median deal size hit roughly $287 million, more than double what it was in early 2025.
But today's investors are picky. Most successful 2026 IPOs have featured drugs in Phase 2 or later. Attovia is still in Phase 1, which makes this filing a test of whether a compelling platform story, a blue-chip investor syndicate, and a massive target market can compensate for thin clinical data.
Immunology and dermatology happen to be exactly where the market's appetite is strongest. Big pharma faces a wave of patent expirations over the next few years, creating urgent demand for next-generation biologics to backfill revenue. Companies in atopic dermatitis, psoriasis, and inflammatory bowel disease sit squarely in the acquisition sweet spot.
The Bottom Line
Attovia is doing something bold: asking public market investors to fund an early-stage bet against one of the most successful drugs in pharmaceutical history. The science is interesting (ligand traps, bispecifics, quarterly dosing). The investor pedigree is impressive. And the market opportunity is massive by any measure.
But Phase 1 means they're still proving the drug is safe, let alone effective. The road from here to competing with an $18 billion franchise runs through years of trials, billions in spending, and a competitive field that grows more crowded by the quarter. If you're watching this one, patience isn't optional. It's the whole game.
Clinical & Regulatory5 min read
The FDA Wants to Build Drug Factories Inside Hospitals
The FDA proposed a new rule that could let drug manufacturers register entire networks of modular production units as a single facility. For cell and gene therapies, it's the regulatory foundation for a future where your cancer treatment gets made down the hall, not across the country.
